Table 3 Effect of radiation oncologist consultation (compared with urologist management alone) on the odds of active treatment (as compared to no treatment) within the year following prostate cancer diagnosis, among a number of clinical relevant subgroups
Whole cohort | Low-risk prostate cancer (Gleason ≤6, Stage 1, and PSA <10 ng/mL) | Intermediate or high-risk prostate cancer | ||||
|---|---|---|---|---|---|---|
Odds ratio | 95% CI | Odds ratio | 95% CI | Odds ratio | 95% CI | |
Primary analysis | ||||||
Unmatched cohort | 5.72 | 5.43–6.02 | 9.98 | 8.40–11.86 | 3.86 | 3.52–4.24 |
Matched cohort | 3.70 | 3.42–4.01 | 8.40 | 6.65–10.62 | 4.00 | 3.60–4.44 |
Subgroup analysis of age and comorbidity | ||||||
Age <70; comorbidity ≤3 | 2.87 | 2.57–3.20 | 7.21 | 5.81–8.96 | 2.16 | 1.85–2.52 |
Age <70; comorbidity 4 or 5 | 3.86 | 3.23–4.62 | 10.44 | 7.6–15.23 | 2.42 | 1.91–3.07 |
Age >70; comorbidity ≤3 | 16.59 | 13.73–20.05 | 30.83 | 16.65–57.08 | 13.49 | 10.95–16.61 |
Age >70; comorbidity 4 or 5 | 20.18 | 16.35–24.89 | 23.77 | 11.72–48.21 | 17.53 | 13.95–22.02 |
Subgroup analysis of region of residence | ||||||
Urban | 4.72 | 4.36–5.12 | 9.70 | 8.05–11.69 | 3.76 | 3.40–4.15 |
Rural | 6.10 | 4.87–7.65 | 12.65 | 7.83–20.14 | 4.98 | 3.75–6.61 |
Subgroup analysis of patients undergoing initial biopsy at an academic facility | ||||||
4.52 | 3.91–5.24 | 8.99 | 6.25–12.94 | |||
Subgroup analysis of tumour volume among those with low-risk prostate cancer | ||||||
Low volume | 4.46 | 2.14–9.31 | ||||
High volume | 4.93 | 2.07–11.74 | ||||
Subgroup analysis of patients receiving MDA on the same day | ||||||
Urologist alone | referent | Referent | Referent | |||
Same-day RadOnc | 3.61 | 2.96–4.39 | 6.01 | 4.07–8.87 | 3.41 | 2.62–4.43 |
Asynchronous RadOnc | 5.01 | 4.63–5.42 | 10.64 | 8.90–12.72 | 3.91 | 3.55–4.31 |
